ScreenerHero

RVPHReviva Pharmaceuticals Holdings, Inc.

NAS · US · Healthcare · Biotechnology · revivapharma.com
0.5100USD+2.00%Mkt Cap: 6.69M $P/E: —

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap6.69M $
Enterprise Value-13.32M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-19.86M $
Revenue/Share—
Last Price0.5100 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.58
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.36
EPS (TTM)-1.01
EPS (Forward)-0.85
52W Range
0.26201% of range17.20
52W High17.20 USD
52W Low0.2620 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-229.71%
ROA-124.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-24.59M $
CapEx (TTM)—
FCF Margin—
FCF Yield-204.74%
Net Debt-19.75M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.05
Current Ratio3.56
Quick Ratio3.35
Book Value/Sh1.361 USD
Cash/Share1.517 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateMar 9, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)30.00 USD
Upside (mean)+5782.4%
Target Range30.00 USD – 30.00 USD
# Analysts1
Ownership
Shares Out.13.11M
Float11.86M
Insiders7.73%
Institutions8.24%
Short Interest
Short Ratio3.4d
Short % Float14.95%
Short % Out.14.57%
Shares Short1.87M
Short (prev mo.)1.83M
Technical
SMA 500.5461 (-6.6%)
SMA 2003.567 (-85.7%)
Beta0.49
S&P 52W Chg18.16%
Avg Vol (30d)22.19K
Avg Vol (10d)35.14K
Technical Indicators
RSI (14)51.8
MACD-0.0145
MACD Signal-0.0282
MACD Hist.+0.0137
BB Upper0.5283 USD
BB Middle0.4541 USD
BB Lower0.3798 USD
BB Width32.70%
ATR (14)0.0744 USD
Vol Ratio (20d)0.66x